Skip to main content

Advertisement

Log in

Prognostic value of K-ras mutation status and subtypes in endoscopic ultrasound-guided fine-needle aspiration specimens from patients with unresectable pancreatic cancer

  • Original Article—Liver, Pancreas, and Biliary Tract
  • Published:
Journal of Gastroenterology Aims and scope Submit manuscript

Abstract

Background

Although recent reports indicate that K-ras mutation status is a biomarker that acts as a prognostic factor, only a few analyses of K-ras mutation subtypes have been published. In addition, there are no reports that analyze overall survival and prognostic factors according to K-ras mutation status and subtypes in only unresectable pancreatic cancer (PC) determined from tissues obtained by endoscopic ultrasound-guided fine-needle aspiration.

Methods

We retrospectively analyzed 242 patients who were diagnosed as having unresectable PC with available histological diagnosis. Clinical data collected included sex, age, Eastern Cooperative Oncology Group performance status, carbohydrate antigen (CA) 19-9, primary tumor location, stage (local or metastatic) according to TNM staging, first-line chemotherapy, K-ras mutation status and subtypes (G12D, G12V, and G12R), and overall survival. We analyzed the negative prognostic factors for reduced overall survival in unresectable PC patients using these data.

Results

From multivariate analysis, CA19-9 ≥1000 U/ml (hazard ratio [HR] 1.78, 95 % confidence interval [CI] 1.28–2.46, P < 0.01), metastatic stage (HR 2.26, 95 % CI 1.58–3.24, P < 0.01), and mutant-K-ras (HR 1.76, 95 % CI 1.03–3.01, P = 0.04) were negative prognostic factors, indicating a reduced survival. Among the patients who had K-ras mutation subtypes, CA19-9 ≥1000 U/ml (HR 1.65, 95 % CI 1.12–2.37, P < 0.01), metastatic stage (HR 2.12, 95 % CI 1.44–3.14, P < 0.01), and the presence of the G12D or G12R mutations (HR 1.60, 95 % CI 1.11–2.28) were negative prognostic factors for overall survival.

Conclusions

K-ras mutation status and subtypes may be associated with survival duration in pancreatic cancer patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Gudjonsson B. Cancer of the pancreas: 50 years of surgery. Cancer. 1987;60:2284–303.

    Article  PubMed  CAS  Google Scholar 

  2. Warshaw AL. Fernandez del Castillo C. Pancreatic carcinoma. N Engl J Med. 1992;326:455–65.

    Article  PubMed  CAS  Google Scholar 

  3. Krishnan S, Rana V, Janjan NA, Abbruzzese JL, Gould MS, Das P, et al. Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation. Cancer. 2006;107:2589–96.

    Article  PubMed  CAS  Google Scholar 

  4. Koom WS, Seong J, Kim YB, Pyun HO, Song SY. CA19-9 as a predictor for response and survival in advanced pancreatic cancer patients treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2009;73:1148–54.

    Article  PubMed  CAS  Google Scholar 

  5. Sawaki A, Kanemitsu Y, Mizuno N, Takahashi K, Nakamura T, Ioka T, et al. Practical prognosis index for patients with metastatic pancreatic cancer treated with gemcitabine. J Gastroenterol Hepatol. 2008;23:1292–7.

    Article  PubMed  CAS  Google Scholar 

  6. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell. 1988;53:549–54.

    Article  PubMed  CAS  Google Scholar 

  7. Tada M, Omata M, Ohto M. Clinical application of ras gene mutation for diagnosis of pancreatic adenocarcinoma. Gastroenterology. 1991;100:233–8.

    PubMed  CAS  Google Scholar 

  8. Kullmann F, Hartmann A, Stohr R, Messmann H, Dollinger MM, Trojan J, et al. KRAS mutation in metastatic pancreatic ductal adenocarcinoma: results of a multicenter phase II study evaluating efficacy of cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line therapy. Oncology. 2011;81:3–8.

    Article  PubMed  CAS  Google Scholar 

  9. Lee J, Jang KT, Ki CS, Lim T, Park YS, Lim HY, et al. Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma. Cancer. 2007;109:1561–9.

    Article  PubMed  CAS  Google Scholar 

  10. Chen H, Tu H, Meng ZQ, Chen Z, Wang P, Liu LM. K-ras mutational status predicts poor prognosis in unresectable pancreatic cancer. Eur J Surg Oncol. 2010;36:657–62.

    Article  PubMed  CAS  Google Scholar 

  11. Kawesha A, Ghaneh P, Andren-Sandberg A, Ograed D, Skar R, Dawiskiba S, et al. K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16(INK4A), p21(WAF-1), cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma. Int J Cancer. 2000;89:469–74.

    Article  PubMed  CAS  Google Scholar 

  12. Immervoll H, Hoem D, Kuqarajh K, Steine SJ, Molven A. Molecular analysis of the EGFR-RAS-RAF pathway in pancreatic ductal adenocarcinomas: lack of mutations in the BRAF and EGFR genes. Virchows Arch. 2006;448:788–96.

    Article  PubMed  CAS  Google Scholar 

  13. Ogura T, Yamao K, Sawaki A, Mizuno M, Hara K, et al. Clinical impact of K-ras mutation analysis in Endoscopic ultrasound-guided fine needle aspiration specimens from pancreatic masses. Gastrointest Endosc. 2012;75:769–74.

    Article  PubMed  Google Scholar 

  14. Chang KJ, Nguyen P, Erickson RA, Durbin TE, Katz KD. The clinical utility of endoscopic ultrasound-guided fine needle aspiration in the diagnosis and staging of pancreatic carcinoma. Gastrointest Endosc. 1997;45:387–93.

    Article  PubMed  CAS  Google Scholar 

  15. Yamao K, Sawaki A, Mizuno N, Shimizu Y, Yatabe Y, Koshikawa T. Endoscopic ultrasound-guided fine-needle aspiration biopsy (EUS-FNAB): past, present, and future. J Gastroenterol. 2005;40:1013–23.

    Article  PubMed  Google Scholar 

  16. Yatabe Y, Koqa T, Mitsudomi T, Takahashi T. CK20 expression, CDX2 expression, K-ras mutation, and goblet cell morphology in a subset of lung adenocarcinomas. J Pathol. 2004;203:645–52.

    Article  PubMed  CAS  Google Scholar 

  17. Yatabe Y, Hida T, Horio Y, Kosaka T, Takahashi T, Mitudomi T. A rapid, sensitive assay to detect EGFR mutation in small biopsy specimens from lung cancer. J Mol Diagn. 2006;8:335–41.

    Article  PubMed  CAS  Google Scholar 

  18. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:1413–7.

    Article  Google Scholar 

  19. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163–70.

    PubMed  CAS  Google Scholar 

  20. Cox DR. Regression models and life-tables. J R Stat Soc B. 1984;34:588–91.

    Google Scholar 

  21. Rozenblum E, Shutte M, Goggins M, Hahn SA, Panzer S, Zahurak M, et al. Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res. 1997;57:1731–4.

    PubMed  CAS  Google Scholar 

  22. Hiyama E, Kodama T, Shinbara K, Iwao T, Itho M, Hiyama K, et al. Telomerase activity is deleted in pancreatic cancer but not in benign tumors. Cancer Res. 1997;57:326–31.

    PubMed  CAS  Google Scholar 

  23. Koorstra JBM, Hustinx SR, Offerhaus GJA, Maitra A. Pancreatic carcinogenesis. Pancreatology. 2008;8:110–25.

    Article  PubMed  Google Scholar 

  24. Karapetis CS, Khambata-Ford S, Jonker DJ, O’Callaghan CJ, Tu D, Tebutt NC, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359:1757–65.

    Article  PubMed  CAS  Google Scholar 

  25. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–16.

    Article  PubMed  CAS  Google Scholar 

  26. Hruban RH, Goggins M, Parsons J, Kem SE. Progression model for pancreatic cancer. Clin Cancer Res. 2000;6:2969–72.

    PubMed  CAS  Google Scholar 

  27. Span M, Moerkerek PT, De Goeij AF, Arends JW. A detailed analysis of K-ras point mutations in relation to tumor progression and survival in colorectal cancer patients. Int J Cancer. 1996;69:241–5.

    Article  PubMed  CAS  Google Scholar 

  28. Andreyev NJH, Norman AR, Cunningham D, Oates J, Dix BR, Dix BR, Iacopetta BJ, et al. Kirsten ras mutations in patients with colorectal cancer: the multicenter ‘RASCAL’ study. Br J Cancer. 2001;85:692–6.

    Article  PubMed  CAS  Google Scholar 

  29. Vega J, Iniesta P, Caldes T, Sanchez A, Lopez J, Dejuan C, et al. Association of K-ras codon 12 transversions with short survival in non-small cell lung cancer. Int J Oncol. 1996;9:1307–11.

    PubMed  CAS  Google Scholar 

  30. Keohavong P, Demichele MAA, Melacrions AC, Landreneau RJ, Weyant RJ, Siegfried JM. Detection of K-ras mutations in lung carcinomas-relationship to prognosis. Clin Cancer Res. 1999;2:411–8.

    Google Scholar 

  31. John J, Frech M, Wittinghofer A. Biochemical properties of Ha-ras encoded p21 mutants and mechanism of the autophosphorylation resection. J Biol Chem. 1998;263:792–9.

    Google Scholar 

  32. Krengle U, Schlichting L, Scherer A, Schumann R, Frech M, John J, et al. Three-dimensional structures of H-ras p21 mutants: molecular basis for their inability to function as signal switch molecules. J Biol Chem. 1989;264:86–92.

    Google Scholar 

  33. Al-Mulla F, Mackenzie EM. Differences in in vitro invasive capacity induced by differences in Ki-Ras protein mutations. J Pathol. 2001;195:549–56.

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflicts of interest.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Kenji Yamao.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ogura, T., Yamao, K., Hara, K. et al. Prognostic value of K-ras mutation status and subtypes in endoscopic ultrasound-guided fine-needle aspiration specimens from patients with unresectable pancreatic cancer. J Gastroenterol 48, 640–646 (2013). https://doi.org/10.1007/s00535-012-0664-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00535-012-0664-2

Keywords

Navigation